Allergen, Individual-Tree pollen Eucalyptus Nilgiri (Safeda ) T18

The Allergen, Individual-Tree Pollen Eucalyptus Nilgiri (Safeda) T18 is a lab-at-home allergy test that detects sensitization to Eucalyptus nilgiri (commonly known as Safeda) pollen by measuring allergen-specific IgE antibodies. This targeted test helps identify whether symptoms such as seasonal rhinitis, allergic conjunctivitis or asthma are driven by sensitization to Eucalyptus pollen. Samples are collected at home by a trained phlebotomist or via an approved self-collection kit and processed in an accredited laboratory to provide clinically actionable results for your clinician in Dubai and across the UAE.

This test is particularly useful for residents exposed to eucalyptus trees in urban landscaping or during outdoor activities, allowing physicians to personalise management — including avoidance strategies, pharmacotherapy adjustments, or consideration of allergen immunotherapy. A positive specific-IgE result indicates sensitization but should be interpreted alongside clinical history and symptom patterns; your allergist or GP in Dubai can help translate results into a treatment plan and follow-up recommendations.

• Eucalyptus Nilgiri (Safeda) specific IgE
• Specific IgE concentration (kU/L)
• Sensitization class (0–6)

• Recurrent seasonal nasal congestion or sneezing during local eucalyptus flowering
• Unexplained or seasonal asthma exacerbations
• Persistent allergic conjunctivitis linked to outdoor exposure
• Before initiating allergen-specific immunotherapy
• When targeted avoidance measures are being considered

• Identifies sensitization to Eucalyptus (Safeda) pollen for precise diagnosis
• Enables tailored treatment and avoidance strategies
• Supports clinical decisions on immunotherapy eligibility
• Convenient at-home sample collection across Dubai and the UAE
• Timely laboratory reporting to your treating clinician for action

• At-home blood sample collection (venous phlebotomy or approved DBS kit) by trained staff
• No fasting required prior to sample collection
• Inform your clinician if you are receiving allergen immunotherapy or biologic agents (e.g., omalizumab)
• Pediatric collection available — specify age at booking for appropriate kit or personnel